Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination
Purpose : Hepatitis B virus (HBV) vaccination is recommended for all human immunodeficiency virus (HIV)-infected patients without HBV immunity. However, serological response to standard HBV vaccination is frequently suboptimal in this population and the appropriate strategy for revaccination of HIV-...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Perspectives in Clinical Research |
Subjects: | |
Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2014;volume=5;issue=3;spage=134;epage=138;aulast=Ramezani |
id |
doaj-ee7ec1ca7c024eb8af9dc9c2f513ea33 |
---|---|
record_format |
Article |
spelling |
doaj-ee7ec1ca7c024eb8af9dc9c2f513ea332020-11-24T21:32:05ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852014-01-015313413810.4103/2229-3485.134318Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccinationAmitis RamezaniAlireza JanbakhshMaryam Gol-MohammadiMohammad BanifazlArezoo AghakhaniAli EslamifarZahra PournasiriBehzad MahdavianAli-Asghar FaraziMasoomeh SofianPurpose : Hepatitis B virus (HBV) vaccination is recommended for all human immunodeficiency virus (HIV)-infected patients without HBV immunity. However, serological response to standard HBV vaccination is frequently suboptimal in this population and the appropriate strategy for revaccination of HIV-infected nonresponders remained controversial. We aimed to determine the serological response to one booster dose of HBV vaccine given by intradermal (ID) or intramuscular (IM) route in HIV-positive nonresponders to standard HBV vaccination. Materials and Methods : In this study, 42 HIV-infected nonresponders were enrolled. We randomized them to receive either 10 μg (0.5 mL) for ID (20 cases) or 20 μg (1 mL) for IM (22 cases) administration of HBV vaccine as a one booster dose. After 1 month, anti-HBs titer was checked in all cases. A protective antibody response (seroconversion) defined as an anti-HBs titer ≥10 IU/L. Results: Seroconversion was observed in 47.6% of subjects after 1 ID dose. A total of 30% showed antibody titers above 100 IU/L. Except one case, all responders had CD4 + >200 cells/mm 3 . Mean anti-HBs titer was 146.5 ± 246 IU/L. After the one IM booster dose, seroconversion was observed in 50% of cases. A total of 36.3% of subjects had anti-HBs ≥100 IU/L. All responders had CD4 + >200 cells/mm 3 , except one case. Mean anti-HBs titer was 416.4 ± 765.6 IU/L. Responders showed significantly higher CD4 + cell counts, in comparison to nonresponders (P < 0.001). Conclusions: One booster dose administered IM or ID to HIV-infected nonresponders resulted in similar rates of seroconversion, overall response rate 50%. However, higher anti-HBs titers observed more frequently in IM group.http://www.picronline.org/article.asp?issn=2229-3485;year=2014;volume=5;issue=3;spage=134;epage=138;aulast=RamezaniBooster dosehepatitis B virus vaccinationhuman immunodeficiency virusintradermalintramuscularnonresponder |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Amitis Ramezani Alireza Janbakhsh Maryam Gol-Mohammadi Mohammad Banifazl Arezoo Aghakhani Ali Eslamifar Zahra Pournasiri Behzad Mahdavian Ali-Asghar Farazi Masoomeh Sofian |
spellingShingle |
Amitis Ramezani Alireza Janbakhsh Maryam Gol-Mohammadi Mohammad Banifazl Arezoo Aghakhani Ali Eslamifar Zahra Pournasiri Behzad Mahdavian Ali-Asghar Farazi Masoomeh Sofian Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination Perspectives in Clinical Research Booster dose hepatitis B virus vaccination human immunodeficiency virus intradermal intramuscular nonresponder |
author_facet |
Amitis Ramezani Alireza Janbakhsh Maryam Gol-Mohammadi Mohammad Banifazl Arezoo Aghakhani Ali Eslamifar Zahra Pournasiri Behzad Mahdavian Ali-Asghar Farazi Masoomeh Sofian |
author_sort |
Amitis Ramezani |
title |
Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
title_short |
Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
title_full |
Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
title_fullStr |
Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
title_full_unstemmed |
Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
title_sort |
serological response to one intradermal or intramuscular hepatitis b virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination |
publisher |
Wolters Kluwer Medknow Publications |
series |
Perspectives in Clinical Research |
issn |
2229-3485 |
publishDate |
2014-01-01 |
description |
Purpose : Hepatitis B virus (HBV) vaccination is recommended for all human immunodeficiency virus (HIV)-infected patients without HBV immunity. However, serological response to standard HBV vaccination is frequently suboptimal in this population and the appropriate strategy for revaccination of HIV-infected nonresponders remained controversial. We aimed to determine the serological response to one booster dose of HBV vaccine given by intradermal (ID) or intramuscular (IM) route in HIV-positive nonresponders to standard HBV vaccination. Materials and Methods : In this study, 42 HIV-infected nonresponders were enrolled. We randomized them to receive either 10 μg (0.5 mL) for ID (20 cases) or 20 μg (1 mL) for IM (22 cases) administration of HBV vaccine as a one booster dose. After 1 month, anti-HBs titer was checked in all cases. A protective antibody response (seroconversion) defined as an anti-HBs titer ≥10 IU/L. Results: Seroconversion was observed in 47.6% of subjects after 1 ID dose. A total of 30% showed antibody titers above 100 IU/L. Except one case, all responders had CD4 + >200 cells/mm 3 . Mean anti-HBs titer was 146.5 ± 246 IU/L. After the one IM booster dose, seroconversion was observed in 50% of cases. A total of 36.3% of subjects had anti-HBs ≥100 IU/L. All responders had CD4 + >200 cells/mm 3 , except one case. Mean anti-HBs titer was 416.4 ± 765.6 IU/L. Responders showed significantly higher CD4 + cell counts, in comparison to nonresponders (P < 0.001). Conclusions: One booster dose administered IM or ID to HIV-infected nonresponders resulted in similar rates of seroconversion, overall response rate 50%. However, higher anti-HBs titers observed more frequently in IM group. |
topic |
Booster dose hepatitis B virus vaccination human immunodeficiency virus intradermal intramuscular nonresponder |
url |
http://www.picronline.org/article.asp?issn=2229-3485;year=2014;volume=5;issue=3;spage=134;epage=138;aulast=Ramezani |
work_keys_str_mv |
AT amitisramezani serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT alirezajanbakhsh serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT maryamgolmohammadi serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT mohammadbanifazl serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT arezooaghakhani serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT alieslamifar serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT zahrapournasiri serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT behzadmahdavian serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT aliasgharfarazi serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination AT masoomehsofian serologicalresponsetooneintradermalorintramuscularhepatitisbvirusvaccineboosterdoseinhumanimmunodeficiencyvirusinfectednonresponderstostandardvaccination |
_version_ |
1725958754709536768 |